AgomAb Therapeutics NV

AGMB chart

AgomAb Therapeutics NV news

• AgomAb Therapeutics (Nasdaq:AGMB) - Stock Analysis

  Simply Wall Street · Oct 25, 3:00 AM EDT

• AgomAb Therapeutics NV ADR Estimates – FWB:M5E

  TradingView · Oct 24, 12:48 AM EDT

• Insider Stock Purchases: October 22, 2026

  Quiver Quantitative · Oct 22, 2:45 PM EDT

• Director David Epstein Buys 10,000 Shares of AgomAb Therapeutics NV (AGMB)

  GuruFocus · Oct 22, 1:20 PM EDT

• Form 4 AgomAb Therapeutics NV: David R. Epstein (Director) For: 21 October

  Investing.com Nigeria · Oct 22, 9:09 AM EDT

• Two 5,000-share purchases mark director David R. Epstein’s buying in AgomAb Therapeutics (AGMB).

  Stock Titan · Oct 22, 8:15 AM EDT

• Analysts Offer Insights on Healthcare Companies: AgomAb Therapeutics NV ADR (AGMB) and Evaxion Biotech (EVAX)

  The Globe and Mail · Oct 21, 4:44 PM EDT

• Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease

  Yahoo Finance · Oct 13, 4:05 PM EDT

• Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation

  Yahoo Finance · Oct 8, 4:05 PM EDT

• Agomab stock jumps on positive trial data

  Yahoo Finance · Oct 1, 9:27 AM EDT

• Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease

  Yahoo Finance · Oct 1, 6:30 AM EDT

• Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study

  Yahoo Finance · Sep 14, 4:05 PM EDT

AgomAb Therapeutics NV key financials

No XBRL financial data is available for this company yet.

Calendar-year figures as reported to the SEC in XBRL filings.

Recent SEC filings

• 6-KFORM 6-K2026-10-13
• 6-KFORM 6-K2026-10-01
• 6-KFORM 6-K2026-09-14
• 6-KFORM 6-K2026-09-11
• 6-KFORM 6-K2026-08-10
• 6-K6-K2026-08-06
• 6-KFORM 6-K2026-06-23
• 6-KFORM 6-K2026-05-27
• 6-KFORM 6-K2026-04-24
• 20-FFORM 20-F2026-04-23
• 6-KFORM 6-K2026-03-05
• 6-KFORM 6-K2026-02-09

About AgomAb Therapeutics NV

Ticker

AGMB (Nasdaq)

Industry

Biological Products, (No Diagnostic Substances)

Headquarters

Antwerpen

Incorporated in

Belgium

Fiscal year end

December 31

SEC CIK

2020932

Frequently asked questions